Microtubule Inhibitors Induce Cross‐Resistance to Osimertinib Through CaMKII Activation in EGFR ‐Mutated NSCLC
Cancer Science · 2026
DOI: 10.1111/cas.70274 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Kento Kono und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology and Respiratory Medicine, Department of Internal Medicine, Shimane University Faculty of Medicine, Izumo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Lung Neoplasms, Acrylamides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The current standard postoperative adjuvant therapy for patients with epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) includes chemotherapy, including microtubule inhibitors prior to the administration of osimertinib, an EGFR‐tyrosine kinase inhibitor (TKI). However, multidrug resistance following treatment with microtubule inhibitors has been reported, and the optimal sequence of drug administration for EGFR‐mutated NSCLC remains undefined. In this study, we investigated whether prior treatment with microtubule inhibitors induces acquired cross‐resistance to osimertinib in EGFR‐mutated NSCLC cells in vitro. To model acquired resistance, PC‐9 cells were exposed to vinorelbine or paclitaxel for 18 weeks—approximating the clinical duration of four adjuvant chemotherapy cycles—and subsequent drug sensitivity and signaling pathway alterations were assessed using cell viability assays, RNA sequencing, and immunoblotting. We found that two human NSCLC cell lines derived from PC‐9 exhibited reduced sensitivity to osimertinib after 18 weeks of in vitro treatment with tubulin inhibitors: vinorelbine (PC‐9/VNR) and paclitaxel (PC‐9/PTX). Furthermore, PC‐9/VNR and PC‐9/PTX cells showed activation of FZD7 and calcium/calmodulin‐dependent protein kinase II (CaMKII), along with increased sensitivity to the CaMKII inhibitor KN‐93, which exerted additive or synergistic effects. These findings suggest that CaMKII plays a critical role in EGFR‐TKI resistance. This study underscores the importance of optimizing the timing of EGFR‐TKI administration in the therapeutic sequence for EGFR‐mutated NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology and Respiratory Medicine, Department of Internal Medicine, Shimane University Faculty of Medicine, Izumo, Japan.
ORCID-Profile: Kento Kono, Ryosuke Tanino
Zitieren
APA
Kono, K., Tanino, R., Tsubata, Y., Haque, E. F., Isobe, T., & Okimoto, T. (2026). Microtubule Inhibitors Induce Cross‐Resistance to Osimertinib Through CaMKII Activation in EGFR ‐Mutated NSCLC. Cancer Science. https://doi.org/10.1111/cas.70274
Vancouver
Kono K, Tanino R, Tsubata Y, Haque EF, Isobe T, Okimoto T. Microtubule Inhibitors Induce Cross‐Resistance to Osimertinib Through CaMKII Activation in EGFR ‐Mutated NSCLC. Cancer Science. 2026. doi:10.1111/cas.70274
BibTeX
@article{Kono2026,
author = {Kono, Kento and Tanino, Ryosuke and Tsubata, Yukari and Haque, Eshat Fahmida and Isobe, Takeshi and Okimoto, Tamio},
title = {Microtubule Inhibitors Induce Cross‐Resistance to Osimertinib Through CaMKII Activation in EGFR ‐Mutated NSCLC},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70274}
}
EUVIMED